Abstract
A selective and a highly sensitive method for the determination of the non-nucleoside reverse transcriptase inhibitor (NNRTI), efavirenz, in human plasma has been developed and fully validated based on high performance liquid chromatography tandem mass spectrometry (LC–MS/MS). Sample preparation involved protein precipitation followed by one to one dilution with water. The analyte, efavirenz was separated by high performance liquid chromatography and detected with tandem mass spectrometry in negative ionization mode with multiple reaction monitoring. Efavirenz and 13C6-efavirenz (Internal Standard), respectively, were detected via the following MRM transitions: m/z 314.20243.90 and m/z 320.20249.90. A gradient program was used to elute the analytes using 0.1% formic acid in water and 0.1% formic acid in acetonitrile as mobile phase solvents, at a flow-rate of 0.3 mL/min. The total run time was 5 min and the retention times for the internal standard (13C6-efavirenz) and efavirenz was approximately 2.6 min. The calibration curves showed linearity (coefficient of regression, r>0.99) over the concentration range of 1.0–2,500 ng/mL. The intraday precision based on the standard deviation of replicates of lower limit of quantification (LLOQ) was 9.24% and for quality control (QC) samples ranged from 2.41% to 6.42% and with accuracy from 112% and 100–111% for LLOQ and QC samples. The inter day precision was 12.3% and 3.03–9.18% for LLOQ and quality controls samples, and the accuracy was 108% and 95.2–108% for LLOQ and QC samples. Stability studies showed that efavirenz was stable during the expected conditions for sample preparation and storage. The lower limit of quantification for efavirenz was 1 ng/mL. The analytical method showed excellent sensitivity, precision, and accuracy. This method is robust and is being successfully applied for therapeutic drug monitoring and pharmacokinetic studies in HIV-infected patients.
Highlights
Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in the treatment of HIV-1 infection in combination with other anti-retroviral agents in children and adults
The analytical method is fully validated in accordance with Food and Drug Administration (FDA) guidelines [27], using LC-MS/MS tandem mass spectrometry
For stability studies and sample analysis only low, medium and high quality control (QC) are used for accepting the batch
Summary
Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in the treatment of HIV-1 infection in combination with other anti-retroviral agents in children and adults. HPLC/UV- based methods aim at simultaneous quantification of several drugs, but has limited selectivity and sensitivity. This requires a relatively long run time and high sample volume. Different sample preparation methods, such as liquidliquid extraction [4,5,8] solid phase extraction [3,9,10,11,12], and protein precipitation followed by dilution [5] have been used to extract efavirenz from plasma. All methods use a complicated time-consuming sample pre-treatment consisting of solid-phase or liquid–liquid extraction combined with evaporation of the extract to dryness, which is subsequently reconstituted. We report a rapid, selective, sensitive, reproducible and cost effective bioanalytical method for the determination of efavirenz in human plasma. The analytical method is fully validated in accordance with FDA guidelines [27], using LC-MS/MS tandem mass spectrometry
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
